Loading company…
Shanghai Taichu Biotechnology provides CRO and CDMO services for drug research, development, and production.
Established in 2020 and based in Shanghai, China, Shanghai Taichu Biotechnology provides contract research and development and manufacturing services. Its CRO work includes nonclinical drug efficacy evaluation and antibody drug discovery. CDMO services cover antibody drug processes, high-end formulation delivery systems, and small nucleic acid processes. In May 2023, it raised approximately CNY 400 million in Series A funding led by IDG Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in